Folia Health获得1050万美元A轮融资，利用患者报告的信息变革医疗保健和研究-动脉网

Folia Health Secures $10.5M in Funding to Transform Healthcare and Research With Patient-Reported Information

Healthcare IT Today 等信源发布 2025-11-06 22:41



可切换为仅中文







Series A Investment Will Advance the Company’s Efforts to Give Patients the Power to Drive Research on Rare Diseases and Chronic Conditions

A轮融资将推动公司赋予患者推动罕见病和慢性病研究的能力。

Folia Health

健康嘉年华

, the patient-driven health company and pioneer of home-reported outcomes (HROs), committed to transforming lived experiences into structured data insights to advance research and personalized care, today announced the close of a $10.5 million Series A funding round led by

，这家以患者为中心的健康公司和家庭报告结果（HROs）的先驱，致力于将生活体验转化为结构化数据洞察，以推动研究和个性化护理，今天宣布完成了由...领投的1050万美元A轮融资。

S3 Ventures

S3 创投

, alongside longtime partner

，与长期合作伙伴一起

Crosslink Capital

交叉资本

and specialist fund

和专业基金

Create Health Ventures

创建健康风险投资

. The investment will enable the company to double down on its mission to put power in the hands of patients, whose firsthand experiences with chronic and rare conditions make them valuable — and underutilized — healthcare experts.

这项投资将使该公司能够加倍努力，实现其赋予患者权力的使命，这些患者亲身经历慢性病和罕见病，这使他们成为宝贵且未被充分利用的医疗专家。

Folia’s platform enables individuals to track symptoms, treatments, and outcomes, and share them with unprecedented control. The company’s commitment to consent and radical transparency means that any data used for external research requires explicit consent, participants can see exactly how their information is being used and what is being learned through detailed Participant Reports, and can withdraw participation at any time.

Folia的平台使个人能够追踪症状、治疗和结果，并以空前的控制力进行分享。公司对同意和彻底透明的承诺意味着，任何用于外部研究的数据都需要明确的同意，参与者可以准确地看到他们的信息是如何被使用的，以及通过详细的参与者报告学到了什么，并且可以随时退出参与。

Folia also recognizes participants for their contributions to research studies through its revenue-sharing program, Data Dividends..

Folia还通过其收入共享计划Data Dividends，表彰参与者对研究的贡献。

“This funding is an affirmation of our fierce dedication to making patient-focused healthcare a reality. Instead of trying to fix the system from the outside in, we’ve built Folia to harness the power of each individual patient — to make their healthcare make sense,” said company founder and CEO Nell Meosky Luo.

“这笔资金肯定了我们对实现以患者为中心的医疗保健的坚定承诺。我们并没有试图从外部修复系统，而是构建了Folia来发挥每位患者的潜力 — 让他们的医疗保健变得有意义，”公司创始人兼首席执行官Nell Meosky Luo表示。

“People live in their bodies 24/7 — they notice patterns, track what works, spot when something’s off. Your own insights reveal your most burdensome symptoms, how different treatments and other things you’re trying are working for you; and also, the massive difference it can make when your treatments are working well.

“人们无时无刻不生活在自己的身体里——他们会注意到规律，追踪什么方法有效，发现何时出现问题。你自己的见解揭示了你最沉重的症状、不同治疗方法以及其他你正在尝试的事物对你的效果；同时，当治疗奏效时，它能带来的巨大差异也显而易见。”

The knowledge held by each of our participants fills crucial knowledge gaps in traditional health data, which focuses on what happens when you’re at the clinic.”.

我们的每位参与者所掌握的知识填补了传统健康数据中的关键知识空白，这些数据关注的是你去诊所时发生的情况。

By providing a platform giving direct value to patients, Folia Health’s approach generates high-quality, longitudinal real-world evidence (RWE) for researchers. This has informed FDA discussions and treatment guidelines, led to partnerships with leading life science companies, and generated research-grade data across conditions that have a major impact on people’s lives, including lupus, sickle cell disease, eczema, and paroxysmal nocturnal hemoglobinuria (PNH).

通过提供一个为患者提供直接价值的平台，Folia Health 的方法为研究人员生成了高质量、纵向的真实世界证据 (RWE)。这已经为 FDA 讨论和治疗指南提供了信息，促成了与领先生命科学公司的合作，并在对人们生活有重大影响的疾病领域生成了研究级数据，这些疾病包括狼疮、镰状细胞病、湿疹和阵发性夜间血红蛋白尿 (PNH)。

Other Folia Health initiatives include:.

其他Folia Health的举措包括：。

Active studies across multiple rare kidney diseases in partnership with a major life science organization

与一家主要的生命科学组织合作，针对多种罕见肾脏疾病开展积极研究。

A national study on the impact of Trikafta in cystic fibrosis

全国性研究：Trikafta对囊性纤维化的影响

The first app-based, remote study capturing the daily experiences of people with IgA nephropathy

基于应用程序的首个远程研究，捕捉 IgA 肾病患者的每日体验

Longitudinal research in sickle cell disease that addresses healthcare disparities and pain management challenges

镰状细胞病的纵向研究，关注医疗差异和疼痛管理挑战

Brian R. Smith, Managing Director at S3 Ventures, adds, “Folia is a validated research platform redefining how we understand chronic and rare diseases. Nearly a decade of peer-reviewed research positions Folia as the gold standard for patient-driven real-world evidence, and we are thrilled to support their growth across new conditions and partnerships.”.

S3 Ventures的管理总监布莱恩·R.史密斯补充道：“Folia是一个经过验证的研究平台，重新定义了我们对慢性病和罕见病的理解。近十年的同行评审研究使Folia成为患者驱动的真实世界证据的黄金标准，我们非常高兴能够支持他们在新适应症和合作伙伴关系中的成长。”

With the inevitable shift toward using AI tools to make personal health decisions, data based on real experiences is the foundation that is necessary for AI models to accurately reflect individuals’ unique health journeys. “What gets lost in the excitement over the power of AI is the fact that these new technologies require the right data to give us insights that are meaningful and useful,” said Dan Toffling, Co-Founder and CTO at Folia Health.

随着不可避免地转向使用人工智能工具来做出个人健康决策，基于真实体验的数据是人工智能模型准确反映个人独特健康历程所需的基础。Folia Health联合创始人兼首席技术官丹·托夫林表示：“在对人工智能的强大功能感到兴奋的同时，人们忽略了一个事实，即这些新技术需要正确的数据，才能为我们提供有意义且有用的信息。”

“Right now, we’re dependent on incomplete and skewed datasets, typically information that’s collected a few days out of the year during brief interactions with clinicians. In other words, would you want all your health decisions to be based solely on what’s in your doctor’s notes in your EHR?”.

“目前，我们依赖于不完整且有偏差的数据集，这些数据通常是在一年中的几天内与临床医生短暂互动时收集的。换句话说，你是否希望所有的健康决策都仅仅基于电子健康记录（EHR）中医生的笔记？”

The funding announcement follows Folia’s recent launch of Mosaic, a community insights research initiative that enables participants to ask questions and get answers based on aggregated data from others with similar conditions. The program is currently active for users with eczema and PNH, with plans to expand to lupus and sickle cell disease in 2026..

资金公告发布之际，Folia刚刚推出了名为“Mosaic”的社区洞察研究计划，该计划使参与者能够提问并根据来自具有相似病症的其他参与者的汇总数据获得答案。该项目目前已面向患有湿疹和PNH的用户开放，并计划在2026年扩展至狼疮和镰状细胞病。

About Folia Health

关于Folia Health

Folia Health is a patient-led health company and the pioneer of home-reported outcomes (HROs), transforming lived health experiences into valuable structured data insights to advance research and personalized care. The company’s platform is built on the belief that the knowledge of patients and caregivers is the missing piece to enable precise, individualized care and high-impact research.

Folia Health是一家由患者主导的健康公司，也是家庭报告结果（HROs）的先驱，将真实的健康体验转化为有价值的数据洞察，以推动研究和个性化护理。该公司的平台基于一个信念：患者和护理人员的知识是实现精准个性化护理和高影响力研究的缺失部分。

Through a useful platform, radical transparency, explicit consent protocols, and data dividend payments, Folia bridges the gap between patients, clinicians, and researchers while maintaining the highest standards of data privacy and patient autonomy. Founded in 2016 by family caregivers and based in Boston, Folia works with individuals across chronic and rare conditions to generate clinical-grade real-world evidence.

通过一个有用的平台、彻底的透明度、明确的同意协议和数据红利支付，Folia在保持最高标准的数据隐私和患者自主权的同时，弥合了患者、临床医生和研究人员之间的差距。Folia于2016年由家庭护理人员创立，总部位于波士顿，与跨慢性病和罕见病的个体合作，生成临床级别的真实世界证据。

For more information, visit .

欲了解更多信息，请访问。

foliahealth.com

。

About S3 Ventures

关于S3 Ventures

Founded in 2005, S3 Ventures is one of the largest and longest-serving venture capital firms in Texas. Backed by a philanthropic family with a multi-billion-dollar foundation, they empower visionary founders with the patient capital and true resources required to grow extraordinary, high-impact companies in Business Technology, Digital Experiences, and Healthcare Technology.

成立于2005年的S3 Ventures是德克萨斯州最大且历史最悠久的风险投资公司之一。该公司由一个拥有数十亿美元基金会的慈善家族支持，为富有远见的创始人提供耐心资本和真正资源，助力其在商业技术、数字体验和健康技术领域发展出非凡的高影响力公司。

With $900M+ in assets under management, they lead Seed, Series A, and Series B investments ranging from $500K to $10M with the capacity to invest $20M+ over the lifetime of a company. To learn more, visit .

管理着超过9亿美元的资产，他们主导种子轮、A轮和B轮投资，投资金额从50万美元到1000万美元不等，并有能力在公司生命周期内投资超过2000万美元。欲了解更多信息，请访问。

s3vc.com

。

Originally announced October 1st, 2025

最初宣布于2025年10月1日